Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MDV3100: Interim Phase I/II data

Interim data from the open-label, U.S. Phase I/II trial in 6 patients with HRPC showed

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE